Clinical Trial Search

Phase 3 N=862 Double-blind Placebo-controlled Trial of Generic Clindamycin/Benzoyl Peroxide Gel Versus Onexton Gel in Acne Vulgaris

Acne Vulgaris

Primary: Percent Change in the Inflammatory (Papules and Pustules) Lesion Counts — -63.81; -67.56; -53.78 percentage of change — p=0.0001

Actavis Inc. Results May 2020 0.5% serious AE View details

Phase 3 N=608 A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)

Multiple Sclerosis, Relapsing-Remitting

Primary: Percentage of Participants Without Any Protocol-Defined Events During 96-Week Period — 48.1 Percentage of Participants

Genentech, Inc. Results May 2020 6.7% serious AE View details

Phase 3 N=129 SOFEED: Six Food vs. One Food Eosinophilic Esophagitis Diet Study

Eosinophilic Gastrointestinal Disorders (EGIDs) · Eosinophilic Esophagitis (EoE)

Primary: Percent of Participants in Histologic Remission (<15 Eos/Hpf) — 34.3; 40.3 percentage of participants — p=0.58

Children's Hospital Medical Center, Cincinnati Results May 2020 0.6% serious AE View details

Phase 3 N=550 A Study of the Safety and Efficacy of DFD-03 for the Treatment of Acne Vulgaris

Acne Vulgaris

Primary: Absolute Change in the Inflammatory Lesion Counts on the Face — 30.1; 29.8; 15.4; 16.9 Lesions

Dr. Reddy's Laboratories Limited Results May 2020 0.5% serious AE View details

Phase 3 N=704 Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated Vasculitis

Granulomatosis With Polyangiitis (Wegener's) (GPA) · Microscopic Polyangiitis (MPA)

Primary: Composite of i) All-cause Mortality or ii) End-stage Renal Disease — 100; 109 Participants

University of Pennsylvania Results May 2020 63.8% serious AE View details

Phase 3 N=229 A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes

Myelodysplastic Syndromes

Primary: Percentage Of Participants Who Achieved Red Blood Cell Transfusion Independence (RBC-TI) ≥ 8 Weeks From Week 1 to Week 24 — 37.91; 13.16 Percent of Participants…

Celgene Results May 2020 38.9% serious AE View details

Phase 3 N=62 Prospective Double Blinded Randomized Control Study of the Use of Fibrinogen in High-Risk Cardiac Surgery

Cardiac Complication During Procedure

Primary: Cumulative Transfusion Units — 0; 0 Transfusion Units — p=.908

Nova Scotia Health Authority Results May 2020 25.0% serious AE View details

Phase 3 N=686 Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis

Arthritis, Psoriatic

Primary: Percentage of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 83.7; 16.8 percentage of participants

Pfizer Results May 2020 14.1% serious AE View details

Phase 3 N=131 Palbociclib Plus Letrozole For Postmenopausal Women With HR(+) HER2(-) Advanced Breast Cancer For Whom Letrozole Is Deemed Appropriate

Advanced Breast Cancer Female

Primary: Number of Participants With All-causality Treatment-emergent Adverse Events (TEAEs) — 0; 17; 82; 23 Participants

Pfizer Results May 2020 24.6% serious AE View details

Phase 3 N=72 Heliox-Driven Racemic Epinephrine in Treatment of Bronchiolitis in Pediatric ED Patients

Bronchiolitis

Primary: Change in Modified Wood's Clinical Asthma Score (M-WCAS) From Baseline to 240 Minutes — 1.84; .031 units on a scale — p=<0.05

University of Louisville Results May 2020 0.0% serious AE View details

Phase 3 N=420 An Administration Method Study of Human Regular U-500 Insulin (LY041001) in Participants With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Primary: Change From Baseline in Hemoglobin A1c (HbA1c) — -1.27; -0.85 Percentage of HbA1c — p=<0.001

Eli Lilly and Company Results May 2020 13.6% serious AE View details

Phase 3 N=64 Study of Leuprolide Acetate Injectable Suspension in the Treatment of Central Precocious Puberty

Precocious Puberty, Central

Primary: Percentage of Participants With Suppression of Peak-Stimulated Luteinizing Hormone at 6 Months. — 54 Participants

Tolmar Inc. Results May 2020 1.6% serious AE View details

Phase 3 N=182 A Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine

Melanoma

Primary: Two-Years Survival Rate — 33.98; 34.09 Percentage of Participants — p=0.5059

Bristol-Myers Squibb Results May 2020 26.3% serious AE View details

Phase 3 N=31 A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies

Systemic Juvenile Idiopathic Arthritis · Hereditary Periodic Fevers

Primary: Number of Participants With Adverse Events — 7; 29 Participants

Novartis Pharmaceuticals Results May 2020 22.6% serious AE View details

Phase 3 N=403 A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)

Cystic Fibrosis

Primary: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) — -0.2; 13.6 percentage points — p=<0.0001

Vertex Pharmaceuticals Incorporated Results May 2020 17.4% serious AE View details